Surgery plus TKIs therapy for gastrointestinal stromal tumors

Author:

Yang Tiequan1ORCID,Gao Boyang2ORCID,Zheng Keji3ORCID

Affiliation:

1. Ningbo No.2 Hospital , Ningbo , China

2. Wenzhou Medical University , Wenzhou , Zhejiang , China

3. Yuyao Second People’s Hospital; Maternal and Child Health Hospital of Yuyao , Yuyao , China

Abstract

Abstract Introduction In this era of tyrosine kinase inhibitors (TKIs), the clinical benefit of surgery for patients with metastatic or recurrent gastrointestinal mesenchymal tumor (GIST) is not well defined. The aim of our study was to demonstrate the survival advantage of adding surgery in patients with recurrent or metastatic GIST. Methods A systematic search of PubMed, Web of Knowledge, Ovid’s database was conducted. Relevant studies published by 31 July 2022 on the role of surgery in recurrent or metastatic GIST were identified. Research quality was assessed using the Newcastle-Ottawa Quality Assessment Scale. Results Eight studies involving 842 patients were included. The four included studies covered 3-year survival and included 441 patients, of whom 302 received TKIs, and 139 received TKIs plus surgery. 3-year overall survival was significantly higher in the TKIs plus surgery group than in the TKIs group (OR=2.37, 95% CI 1.45–3.88, P = 0.001). The 5-year overall survival was 69.0% in the TKIs plus surgery group compared with 49.1% in the TKIs only group. Survival was significantly higher in TKIs plus surgery group (OR = 2.69, 95%Cl 1.49–4.86, P=0.001). Four studies, including 453 patients, indicated 3-year progression-free survival (PFS). The pooled analysis revealed the TKIs plus surgery group did have a better PFS than the TKIs only group (OR = 4.02, 95% CI: 1.45–11.16, P=0.008). Three included studies focused on gastrointestinal stromal tumor liver metastasis (GLM). The role of surgery plus TKIs had statistically significant better 5-year overall survival as compared with TKI treatment alone (OR = 2.34, 95% Cl 1.30–4.22, P=0.005). Conclusions Treatment with surgical resection and TKIs could significantly improve the prognosis of patients with recurrent or metastatic GIST.

Publisher

Walter de Gruyter GmbH

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3